Treace Medical Concepts, Inc. (TMCI)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$4.81-1.43%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Treace Medical is growing sales about 5% a year to over $200 million in 2026. The company aims to cut cash usage by 50% in 2026. It has beaten earnings estimates recently despite losses. The stock trades cheaply versus peers.
The company remains unprofitable with negative EPS near -$0.9 in 2026. Cash burn and losses may persist. Management changes and credit agreements add risk. Revenue growth is modest and may stall.
The market expects about 5% revenue growth and continued losses near -$0.9 EPS in 2026. Our fair value near $14 implies the current price reflects a turnaround but with elevated risk. We see potential if cash usage improves as planned.
Breaks if: cash usage reduction less than 25% in FY26
Breaks if: EPS worse than -$1.0 in FY26
Breaks if: revenue falls below $202 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in the healthcare sector. TMCI is currently loss-making, but management is focused on reducing cash usage and driving market share growth.
The market seems to have priced in a justified valuation that is cheap compared to peers, with an expectations gap indicating lower anticipated performance. There is low fragility in the current market regime.
Management has made progress in reducing cash usage and increasing surgeon adoption of its expanded bunion portfolio. However, recent financial performance has been weak, and revenue guidance reflects a slight decline.
The long-term thesis hinges on TMCI's ability to raise guidance in the next quarter and the performance of sector bellwethers like ABT, MDT, and SYK. Additionally, broader economic conditions, particularly job growth, could impact TMCI's performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, TMCI's trajectory will depend on its execution of management priorities and external market conditions. Not investment advice.